Alios BioPharma, Inc., a South San Francisco, CA-based biotechnology company developing proprietary therapeutics for respiratory viral diseases, completed a $41m Series B financing.
The round was led by a new, undisclosed investor with participation from all existing investors Novo Ventures, SR One, Roche Venture Fund and Novartis Ventures.
The company intends to use the funds for continued clinical development of its respiratory portfolio.
Led by Lawrence M. Blatt, PhD, President and Chief Executive Officer, Alios BioPharma is advancing AL-8176, an anti-RSV nucleoside analog now in Phase 2 clinical development, and multiple late-stage preclinical development programs targeting Influenza and Rhinovirus.
FinSMEs
07/04/2014